Role of Acute Therapy

Reinforce the importance of early treatment

WAO/EAACI guidelines for treating hereditary angioedema (HAE) recommend that an acute therapy be part of every HAE treatment plan

Patients are strongly encouraged to6:

  • Carry acute therapy with them at all times
  • Have enough acute treatment for 2 attacks, or at least 2 doses, on hand to be prepared if an attack happens

Treatment of acute HAE attacks should be administered6:

  • As early as possible in an attack
  • For all attacks, regardless of location, as soon as they are clearly recognized
Review the signs and symptoms of an HAE attack with your patients

Review the signs and symptoms of an attack with your patients

  • HAE attacks typically cause swelling of the skin/subcutaneous tissues, the gastrointestinal tract/abdomen, and the upper airways, including the larynx.1,2
  • Many patients may experience prodromal signs before an HAE attack, including a tingling sensation, erythema marginatum (a mild, nonpruritic rash), fatigue, and nausea1,3
Reevaluate each patient's on-demand treatment plan regularly

Reevaluate each patient’s treatment plan regularly

  • Make sure your patients are prepared with a detailed treatment plan4,5
  • Monitor frequency of attacks and efficacy of treatment4
  • Patients should be evaluated for long-term preventive treatment at every doctor's visit, or at least once a year6
Recommend FIRAZYR for all acute HAE attacks-whether they occur at home or away

Recommend FIRAZYR for all acute HAE attacks—whether they occur at home or away

  • As the first prefilled, self-administered, subcutaneous injection, FIRAZYR is ready to use as soon as an attack strikes—no reconstitution/mixing, no dose calculation, no special handling, no dose titration, and no refrigeration7
  • FIRAZYR demonstrated faster symptom relief when compared to placebo in clinical trials7
  • Nine out of 10 HAE attacks were treated with only one injection of FIRAZYR in clinical trials (n=582) and in an international observational study (n=1657)7
  • FIRAZYR is a proven bradykinin B2-receptor antagonist used to treat HAE attacks. By inhibiting bradykinin from binding to the B2 receptor, FIRAZYR reduces the clinical symptoms of an acute episodic attack of HAE.7